Can-Fite BioPharma (CANF) Other Accumulated Expenses (2019 - 2020)
Can-Fite BioPharma's (CANF) quarterly Other Accumulated Expenses came in at $2.7 million in Q2 2020, down 7.4% on a QoQ basis from $2.9 million in Q4 2019.
Can-Fite BioPharma (CANF) Other Accumulated Expenses (2019 - 2020) Analysis & Trends
Can-Fite BioPharma (CANF) has 2 years of Other Accumulated Expenses data on file, last reported at $2.7 million in Q2 2020.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $2.7 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $2.7 million (changed N/A YoY) and the FY2019 annual result came in at $2.9 million, changed N/A from the prior year.
- Other Accumulated Expenses retreated to $2.7 million in Q2 2020, from $2.9 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $2.9 million in Q4 2019 to a low of $2.7 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 2.68 Mn |
| Dec 31, 2019 | 2.89 Mn |